The global breast cancer therapeutics market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. The growing geriatric population who are more susceptible to several chronic illnesses such as cancer is propelling the growth of the global breast cancer therapeutics market.
The rising incidences and high prevalence rate of breast cancer across the world are expected to augment the global breast cancer therapeutics market. With this, extensive investment in research and development activities and technological advancements in cancer biology and pharmacology promote breast cancer therapeutics. Continuous upgrades help increase understanding of breast cancer at the molecular level, and the introduction of novel solutions has assisted in lowering the breast cancer mortality rate over the past few years. Newly developed therapeutics efficiently slow down the growth and proliferation of cancerous cells, which is projected to boost the global breast cancer therapeutics market in the upcoming years.
Rise in Cases of Breast Cancer Augments the Market Growth
The growing prevalence of breast cancer across the globe and the escalating demand for effective treatment for a large number of patients are expected to stimulate the growth of the breast cancer therapeutics market. Breast cancer is considered one of the prevalent forms of cancer across the world, and enhanced diagnostic solutions are expected to propel market growth. The escalating demand for preventive care and early treatment due to its numerous benefits led individuals to go for diagnostic procedures, further driving the global breast cancer therapeutics market growth.
Launch of Awareness Programs by Government Stimulates the Market Growth
The breast cancer screening initiatives by government bodies and supportive programs launched by public organizations are anticipated to stimulate the growth of the global breast cancer therapeutics market. According to the WHO report, early detection of breast cancer assists in minimizing the breast cancer mortality rate and accelerates the survival rate among patients who have breast cancer. Numerous government bodies across the globe encourage people to undergo breast cancer screening, especially women aged 50 and over. The screening initiatives and awareness programs are projected to propel the utilization of drugs for the effective treatment of breast cancer, driving the global breast cancer therapeutics market growth over the forecast period.
Escalating Demand for Targeted Therapy Supports the Market Growth
Treatment for breast cancer across the globe is a challenging task for any medical oncologist. The availability of treatment and choice varies from patient to patient. Targeted therapy is preferred over any other therapy as it precisely targets the breast cancer cells without damaging the surrounding healthy cells. The targeted therapy aids medical professionals in overcoming numerous limitations posed by traditional treatments. Targeted therapy also helps oncologists focus more on preventive care than reactive care. This therapy enhances the treatment efficiency in patients diagnosed with advanced stages of breast cancer, which further contributes to the growth of the global breast cancer therapeutics market.
Click here to download the sample
Market Segmentation
The global breast cancer therapeutics market is segmented into
Market Players
Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG are the leading market players contributing the growth of the global breast cancer therapeutics market.
Attribute | Details |
Base Year | 2021 |
Historic Data | 2017 – 2020 |
Estimated Year | 2022 |
Forecast Period | 2023 – 2027 |
Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | · Therapy · End User |
Regional scope | North America; Asia Pacific; Europe; South America; Middle East & Africa |
Country scope | United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Singapore; Malaysia; Germany; United Kingdom; France; Italy; Spain; Poland; Denmark; Brazil; Argentina; Colombia; Poland; Denmark; Saudi Arabia; South Africa; UAE; Iraq; Turkey |
Key companies profiled | Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |